Latest Insider Transactions at Xtant Medical Holdings, Inc. (XTNT)
This section provides a real-time view of insider transactions for Xtant Medical Holdings, Inc. (XTNT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Xtant Medical Holdings, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Xtant Medical Holdings, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2021
|
Greg Jensen Vice President, Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
156,250
+35.38%
|
-
|
|
Aug 15
2021
|
Matthew Rizzo Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,337
+41.45%
|
-
|
|
Aug 15
2021
|
Michael Eggenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,337
+41.45%
|
-
|
|
Aug 15
2021
|
Robert Mc Namara Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,337
+26.94%
|
-
|
|
Aug 15
2021
|
Jeffrey J Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,337
+26.8%
|
-
|
|
Aug 15
2021
|
John K Bakewell Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,337
+26.8%
|
-
|
|
Aug 15
2021
|
Kevin D Brandt Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,169
-2.22%
|
$7,169
$1.2 P/Share
|
|
Aug 15
2021
|
Kevin D Brandt Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,109
+33.37%
|
-
|
|
Aug 15
2021
|
Orbimed Advisors LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
170,674
+41.45%
|
-
|
|
Jul 09
2021
|
Kevin D Brandt Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,800
-5.17%
|
$8,800
$1.74 P/Share
|
|
Nov 17
2020
|
Matthew Rizzo Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
4,800,000
+2.6%
|
$0
$0.01 P/Share
|
|
Nov 17
2020
|
Michael Eggenberg Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
4,800,000
+2.6%
|
$0
$0.01 P/Share
|
|
Nov 17
2020
|
Orbimed Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
4,800,000
+2.6%
|
$0
$0.01 P/Share
|
|
Nov 15
2020
|
Sean E Browne President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,468,859
+44.96%
|
-
|
|
Oct 01
2020
|
Matthew Rizzo Director |
BUY
Grant, award, or other acquisition
|
Indirect |
58,754,394
+45.46%
|
$58,754,394
$1.07 P/Share
|
|
Oct 01
2020
|
Michael Eggenberg Director |
BUY
Grant, award, or other acquisition
|
Indirect |
58,754,394
+45.46%
|
$58,754,394
$1.07 P/Share
|
|
Oct 01
2020
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
58,754,394
+45.46%
|
$58,754,394
$1.07 P/Share
|
|
Feb 05
2020
|
Orbimed Advisors LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
140,846
+43.56%
|
-
|
|
Oct 30
2019
|
Orbimed Advisors LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
41,666
+50.0%
|
-
|
|
Feb 14
2018
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
945,819
+9.32%
|
$6,620,733
$7.2 P/Share
|
|
Feb 14
2018
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,031,930
+49.32%
|
$56,223,510
$7.2 P/Share
|